JP2012522802A5 - - Google Patents

Download PDF

Info

Publication number
JP2012522802A5
JP2012522802A5 JP2012503723A JP2012503723A JP2012522802A5 JP 2012522802 A5 JP2012522802 A5 JP 2012522802A5 JP 2012503723 A JP2012503723 A JP 2012503723A JP 2012503723 A JP2012503723 A JP 2012503723A JP 2012522802 A5 JP2012522802 A5 JP 2012522802A5
Authority
JP
Japan
Prior art keywords
conjugate
composition
antigen
hyperbranched polymer
helper peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012503723A
Other languages
English (en)
Japanese (ja)
Other versions
JP5661735B2 (ja
JP2012522802A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/029694 external-priority patent/WO2010115046A2/en
Publication of JP2012522802A publication Critical patent/JP2012522802A/ja
Publication of JP2012522802A5 publication Critical patent/JP2012522802A5/ja
Application granted granted Critical
Publication of JP5661735B2 publication Critical patent/JP5661735B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012503723A 2009-04-01 2010-04-01 ワクチン組成物及びその使用方法 Expired - Fee Related JP5661735B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16573209P 2009-04-01 2009-04-01
US61/165,732 2009-04-01
PCT/US2010/029694 WO2010115046A2 (en) 2009-04-01 2010-04-01 Vaccine compositions and methods of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014243829A Division JP2015096520A (ja) 2009-04-01 2014-12-02 ワクチン組成物及びその使用方法

Publications (3)

Publication Number Publication Date
JP2012522802A JP2012522802A (ja) 2012-09-27
JP2012522802A5 true JP2012522802A5 (enExample) 2013-05-23
JP5661735B2 JP5661735B2 (ja) 2015-01-28

Family

ID=42828943

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2012503723A Expired - Fee Related JP5661735B2 (ja) 2009-04-01 2010-04-01 ワクチン組成物及びその使用方法
JP2014243829A Pending JP2015096520A (ja) 2009-04-01 2014-12-02 ワクチン組成物及びその使用方法
JP2016105809A Expired - Fee Related JP6139000B2 (ja) 2009-04-01 2016-05-27 ワクチン組成物及びその使用方法
JP2017086900A Expired - Fee Related JP6321261B2 (ja) 2009-04-01 2017-04-26 ワクチン組成物及びその使用方法

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2014243829A Pending JP2015096520A (ja) 2009-04-01 2014-12-02 ワクチン組成物及びその使用方法
JP2016105809A Expired - Fee Related JP6139000B2 (ja) 2009-04-01 2016-05-27 ワクチン組成物及びその使用方法
JP2017086900A Expired - Fee Related JP6321261B2 (ja) 2009-04-01 2017-04-26 ワクチン組成物及びその使用方法

Country Status (9)

Country Link
US (2) US9764012B2 (enExample)
EP (1) EP2413964B1 (enExample)
JP (4) JP5661735B2 (enExample)
CN (2) CN102448491A (enExample)
AU (1) AU2010232512B2 (enExample)
BR (1) BRPI1016133A2 (enExample)
CA (1) CA2756996C (enExample)
RU (2) RU2016137258A (enExample)
WO (1) WO2010115046A2 (enExample)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2657480T3 (es) 2006-08-11 2018-03-05 Life Sciences Research Partners Vzw Péptidos inmunogénicos y su uso en trastornos inmunitarios
WO2009101205A2 (en) 2008-02-14 2009-08-20 Life Sciences Research Partners Vzw Immunogenic control of tumours and tumour cells
WO2010115046A2 (en) 2009-04-01 2010-10-07 University Of Miami Vaccine compositions and methods of use thereof
CN110542754A (zh) * 2009-05-19 2019-12-06 迈阿密大学 用于体外抗原呈递、评估疫苗功效及生物制剂和药物的免疫毒性的组合物、试剂盒和方法
EA201500447A1 (ru) 2009-05-27 2017-03-31 Селекта Байосайенсиз, Инк. НАЦЕЛЕННЫЕ СИНТЕТИЧЕСКИЕ НАНОНОСИТЕЛИ С pH-ЧУВСТВИТЕЛЬНЫМ ВЫСВОБОЖДЕНИЕМ ИММУНОМОДУЛИРУЮЩИХ СРЕДСТВ
WO2011150264A2 (en) 2010-05-26 2011-12-01 Selecta Biosciences, Inc. Synthetic nanocarrier combination vaccines
EA201390660A1 (ru) 2010-11-05 2013-11-29 Селекта Байосайенсиз, Инк. Модифицированные никотиновые соединения и связанные способы
CA2843274A1 (en) 2011-07-29 2013-02-07 Selecta Biosciences, Inc. Synthetic nanocarriers that generate humoral and cytotoxic t lymphocyte (ctl) immune responses
KR20140084020A (ko) * 2011-09-07 2014-07-04 미다테크 리미티드 나노입자 종양 백신
AU2012306243B2 (en) * 2011-09-07 2016-10-20 Midatech Limited Nanoparticle-peptide compositions
GB201201511D0 (en) * 2012-01-30 2012-03-14 Univ Leuven Kath Modified epitopes for boosting CD4+ T-cell responses
WO2014120804A1 (en) * 2013-01-30 2014-08-07 University Of Miami Enteric coated nanoparticles for oral vaccine and drug delivery and methods of production and use thereof
IN2014CH00386A (enExample) * 2013-02-05 2015-04-03 Nitto Denko Corp
US20140220100A1 (en) * 2013-02-05 2014-08-07 Nitto Denko Corporation Vaccine composition for transdermal administration
US20160030588A1 (en) * 2013-03-15 2016-02-04 University Of Miami Immune-potentiating drug nanocarriers and methods of production and use thereof
GB201309469D0 (en) 2013-05-28 2013-07-10 Imcyse Sa Detection of CD4+ T lymphocytes
EP3038609B1 (en) * 2013-08-27 2021-07-28 Deutsches Krebsforschungszentrum Cytotoxic t cell response modifiers
EP3054971B1 (en) * 2013-10-11 2021-03-10 The United States of America, represented by the Secretary, Department of Health and Human Services Epstein-barr virus vaccines
WO2015116568A2 (en) * 2014-01-28 2015-08-06 University Of Miami Muscle cell-targeting nanoparticles for vaccination and nucleic acid delivery, and methods of production and use thereof
GB201418433D0 (en) 2014-10-17 2014-12-03 Imcyse Sa Novel immunogenic peptides
US10729791B2 (en) 2015-05-18 2020-08-04 Imcyse Sa Animal models for evaluating pharmaceutical compounds
US11007260B2 (en) 2015-07-21 2021-05-18 Modernatx, Inc. Infectious disease vaccines
US11364292B2 (en) 2015-07-21 2022-06-21 Modernatx, Inc. CHIKV RNA vaccines
EP3352785A1 (en) * 2015-09-23 2018-08-01 Massachusetts Institute Of Technology Compositions and methods for modified dendrimer nanoparticle vaccine delivery
EA201891001A1 (ru) 2015-10-22 2018-11-30 МОДЕРНАТиЭкс, ИНК. Вакцины на основе нуклеиновых кислот против вируса ветряной оспы (vzv)
WO2017070624A1 (en) 2015-10-22 2017-04-27 Modernatx, Inc. Tropical disease vaccines
AU2016342376A1 (en) 2015-10-22 2018-06-07 Modernatx, Inc. Sexually transmitted disease vaccines
CA3024705A1 (en) * 2016-05-23 2017-11-30 University Of Miami Compositions for selective humoral responses and methods of use thereof
WO2017216768A1 (en) 2016-06-16 2017-12-21 Association For The Advancement Of Tissue Engineering And Cell Based Technologies And Therapies - A4Tec Dendrimer-derived artificial antigen, methods and uses thereof
WO2018089851A2 (en) 2016-11-11 2018-05-17 Modernatx, Inc. Influenza vaccine
WO2018107088A2 (en) 2016-12-08 2018-06-14 Modernatx, Inc. Respiratory virus nucleic acid vaccines
MA47515A (fr) * 2017-02-16 2019-12-25 Modernatx Inc Compositions immunogènes très puissantes
EP3609534A4 (en) 2017-03-15 2021-01-13 ModernaTX, Inc. WIDE SPECTRUM INFLUENZA VIRUS VACCINE
WO2018170256A1 (en) 2017-03-15 2018-09-20 Modernatx, Inc. Herpes simplex virus vaccine
EP3595713A4 (en) 2017-03-15 2021-01-13 ModernaTX, Inc. Respiratory syncytial virus vaccine
WO2018170270A1 (en) 2017-03-15 2018-09-20 Modernatx, Inc. Varicella zoster virus (vzv) vaccine
WO2018237010A2 (en) * 2017-06-20 2018-12-27 The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Vaccine compositions and methods of using the same
JP7722629B2 (ja) * 2017-07-04 2025-08-13 キュアバック エスイー 新規核酸分子
US10653767B2 (en) 2017-09-14 2020-05-19 Modernatx, Inc. Zika virus MRNA vaccines
EP3743526B1 (en) 2018-01-28 2025-03-12 Enable Biosciences Inc. Reagents and methods for blocking non-specific interactions with nucleic acids
MA54676A (fr) 2018-01-29 2021-11-17 Modernatx Inc Vaccins à base d'arn contre le vrs
TW202028222A (zh) * 2018-11-14 2020-08-01 美商Ionis製藥公司 Foxp3表現之調節劑
US11351242B1 (en) 2019-02-12 2022-06-07 Modernatx, Inc. HMPV/hPIV3 mRNA vaccine composition
WO2020190750A1 (en) 2019-03-15 2020-09-24 Modernatx, Inc. Hiv rna vaccines
CN110448695B (zh) * 2019-08-23 2021-07-27 中山大学肿瘤防治中心 一种mRNA疫苗递送载体及其制备方法
CN113173985A (zh) * 2021-03-24 2021-07-27 深圳市新靶向生物科技有限公司 一种与结直肠癌驱动基因突变相关的抗原肽及其应用
CN120209073B (zh) * 2025-05-28 2025-09-23 北京立康生命科技有限公司 一种有利于抗原呈递的间隔肽

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3023A (en) * 1843-03-30 peters
US8003A (en) * 1851-03-25 Improvement in scythe-tastenings
US20050169900A1 (en) * 1993-02-17 2005-08-04 Sloan Kettering Institute For Cancer Research Allogeneic vaccine and methods to synthesize same
US6864060B1 (en) * 1993-03-31 2005-03-08 Cadus Technologies, Inc. Yeast cells expressing modified G proteins and methods of use therefor
JP3926839B2 (ja) 1993-09-14 2007-06-06 エピミューン,インコーポレイティド 万能dr−結合性ペプチドを用いる免疫応答の改変
CA2184132C (en) 1995-09-21 2011-03-15 Kristina J. Hennessy An adjuvanted vaccine which is substantially free of non-host albumin
US6204250B1 (en) * 1996-11-22 2001-03-20 The Mount Sinai Medical Center Of The City Of New York Immunization of infants
ES2265162T3 (es) * 1997-03-27 2007-02-01 Institut Pasteur Carbohidrato glucopeptido de antigeno multiple, vacuna que comprende el mismo y su utilizacion.
US6201250B1 (en) * 1997-08-22 2001-03-13 Richard C. Morlock Sensor housing for UV curing chamber
CN1325115C (zh) 1998-10-05 2007-07-11 法麦克萨有限公司 Ctl表位和t辅助淋巴细胞表位在免疫接种中的应用
US7807377B2 (en) 1998-10-20 2010-10-05 Salvatore Albani Method of isolating antigen-specific T cells employing artificial antigen presenting cells
US20040241842A1 (en) 1999-04-15 2004-12-02 Monash University Stimulation of thymus for vaccination development
US6632435B1 (en) 1999-10-20 2003-10-14 City Of Hope CTL epitope analogs
JP2003516344A (ja) * 1999-12-13 2003-05-13 エピミューン, インコーポレイテッド Hlaクラスia2腫瘍関連抗原ペプチドおよびワクチン組成物
AUPR011700A0 (en) 2000-09-14 2000-10-05 Austin Research Institute, The Composition comprising immunogenic virus sized particles (VSP)
CA2349506C (en) * 2001-06-14 2009-12-08 Duke University A method for selective expression of therapeutic genes by hyperthermia
EP1473564A4 (en) 2001-09-18 2008-12-10 Greenpeptide Co Ltd METHOD FOR DETECTING CELL IMMUNITY AND ITS APPLICATION TO MEDICAMENTS
CN1615316A (zh) * 2001-11-16 2005-05-11 法麦克萨有限公司 多聚体蛋白质的新免疫原性模拟物
US7261875B2 (en) * 2001-12-21 2007-08-28 Board Of Regents, The University Of Texas System Dendritic poly (amino acid) carriers and methods of use
WO2003075951A2 (en) 2002-03-11 2003-09-18 Pharmexa A/S Novel application of vaccination against tnf-alpha
US20080268457A1 (en) * 2002-11-14 2008-10-30 Dharmacon, Inc. siRNA targeting forkhead box P3 (FOXP3)
CN1809379A (zh) 2003-04-18 2006-07-26 诺伍德免疫学有限公司 先于胸腺再活化的疾病预防和疫苗接种
CN101506266A (zh) 2005-02-01 2009-08-12 梅迪沃什有限公司 疫苗输送组合物及使用方法
US7358231B1 (en) * 2005-12-01 2008-04-15 Applera Corporation Pancreatic cancer secreted targets and uses thereof
WO2007089607A2 (en) * 2006-01-26 2007-08-09 University Of Massachusetts Rna silencing agents for use in therapy and nanotransporters for efficient delivery of same
US8954355B2 (en) * 2006-01-26 2015-02-10 Psi Systems, Inc. Integrated postage and shipping label system
US9511134B2 (en) 2006-05-18 2016-12-06 Epimmune Inc. Inducing immune responses to influenza virus using polypeptide and nucleic acid compositions
WO2008113119A1 (en) 2007-03-16 2008-09-25 Cellestis Limited A cell-mediated immune response assay and kits therefor
WO2008151389A1 (en) * 2007-06-15 2008-12-18 Macfarlane Burnet Institute For Medical Research And Public Health Limited Chemically modified macromolecules
US20090123467A1 (en) * 2007-07-31 2009-05-14 The Johns Hopkins University Polypeptide-Nucleic Acid Conjugate for Immunoprophylaxis or Immunotherapy for Neoplastic or Infectious Disorders
WO2010115046A2 (en) 2009-04-01 2010-10-07 University Of Miami Vaccine compositions and methods of use thereof

Similar Documents

Publication Publication Date Title
JP2012522802A5 (enExample)
Liu et al. Arginine-terminated generation 4 PAMAM dendrimer as an effective nanovector for functional siRNA delivery in vitro and in vivo
El-Sayed et al. Delivery of macromolecules using arginine-rich cell-penetrating peptides: ways to overcome endosomal entrapment
JP6321261B2 (ja) ワクチン組成物及びその使用方法
Waite et al. PAMAM-RGD conjugates enhance siRNA delivery through a multicellular spheroid model of malignant glioma
Hassan et al. Dual stimulation of antigen presenting cells using carbon nanotube-based vaccine delivery system for cancer immunotherapy
Kim et al. Nanosac, a noncationic and soft polyphenol nanocapsule, enables systemic delivery of siRNA to solid tumors
Li et al. Rational design of polymeric hybrid micelles to overcome lymphatic and intracellular delivery barriers in cancer immunotherapy
ES2754239T3 (es) Combinación de vacunación y agonistas de OX40
Deng et al. Self-assembled cationic micelles based on PEG-PLL-PLLeu hybrid polypeptides as highly effective gene vectors
Tanaka et al. Cytoplasm-responsive nanocarriers conjugated with a functional cell-penetrating peptide for systemic siRNA delivery
JP2012521201A5 (enExample)
Zhang et al. Sulfonium-driven neoantigen-released DNA nanodevice as a precise vaccine for tumor immunotherapy and prevention
JP2015529678A5 (enExample)
Avila et al. Gene delivery and immunomodulatory effects of plasmid DNA associated with Branched Amphiphilic Peptide Capsules
EP3630807A1 (en) Pd-1 and ctla-4 dual inhibitor peptides
JP2015533376A5 (enExample)
JP2014502961A5 (enExample)
JP2022517236A (ja) 自己組織化ペプチドナノ粒子およびその使用
Hong et al. An mRNA vaccine against SARS-CoV-2: Lyophilized, liposome-based vaccine candidate EG-COVID induces high levels of virus neutralizing antibodies
Brubaker et al. A cationic micelle complex improves CD8+ T cell responses in vaccination against unmodified protein antigen
Kang et al. Self-assembled nanoparticles based on DNA origami and a nitrated T helper cell epitope as a platform for the development of personalized cancer vaccines
Wang et al. Spatiotemporal Nano‐Regulator Unleashes Anti‐Tumor Immunity by Overcoming Dendritic Cell Tolerance and T Cell Exhaustion in Tumor‐Draining Lymph Nodes
He et al. A novel pan-epitope based nanovaccine self-assembled with CpG enhances immune responses against flavivirus
US20230293448A1 (en) Nanoparticle immunogenic compositions and vaccination methods